TSX runs higher on rate cut expectations
Ceribell, Inc. (CBLL) President and CEO Chao Xingjuan, sold 25,000 shares of common stock on July 7, 2025, for a total of $442,500. The shares were sold at prices ranging from $17.02 to $18.7. The transaction comes as the stock, currently trading at $16.56, has declined 8% over the past week. According to InvestingPro analysis, Ceribell appears slightly overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, the CEO also exercised options to acquire 25,000 shares of Ceribell common stock at an exercise price of $2.24, for a total value of $56,000. The company, currently valued at $619 million, maintains impressive gross profit margins of 87%.
Following these transactions, Chao directly owns 776,022 shares of Ceribell (NASDAQ:CBLL) and indirectly owns 369,088 shares through the ACP 2021 Trust. For deeper insights into insider transactions and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Ceribell Inc. reported a significant 42% increase in revenue for the first quarter of 2025, totaling $20.5 million. Despite a net loss of $12.8 million, the company raised its full-year revenue guidance to between $83 million and $87 million. Ceribell also announced FDA clearance for a new pediatric seizure detection algorithm, expanding its product offerings. In another development, Ceribell has initiated legal action against Natus Medical (TASE:BLWV), alleging patent infringement related to EEG technology, with complaints filed both with the U.S. International Trade Commission and the U.S. District Court in Delaware. Additionally, shareholders approved board nominees and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year. TD Cowen maintained a Buy rating for Ceribell, noting potential benefits from easing US-China trade tensions that could improve the company’s margins. The firm highlighted Ceribell’s strong financial health and resilience, even amid tariff challenges. These developments indicate a period of strategic growth and legal vigilance for Ceribell.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.